Biotech Values

[DewDiligence]

AMGN’s acquisition of BioVex is quite high-risk…

In addition to the program risk stemming from the novel MoA, there is some execution risk in the melanoma setting stemming from the unusual primary endpoint of the phase-3 trial:

http://clinicaltrials.gov/ct2/show/NCT00769704

Primary Outcome Measure: Achieving a statistically significant improvement in durable response rate, defined as the rate of CR or PR lasting continuously for 6 or more months, as compared to control therapy.